Chemistry:Odalasvir
From HandWiki
Odalasvir (INN,[1] previously known as ACH-3102)[2][3] is an investigational new drug in development for the treatment of hepatitis C.[4] It is an NS5A inhibitor.[5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.[6][7][8] It is under development by Achillion Pharmaceuticals.[9]
See also
- Discovery and development of NS5A inhibitors
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73". World Health Organization. p. 38. https://www.who.int/medicines/publications/druginformation/innlists/RL73_pre.pdf.
- ↑ "Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. http://www.achillion.com/ACH3102.
- ↑ "Odalasvir". ChemIDplus. https://pubchem.ncbi.nlm.nih.gov/#tab/sidsrcname=ChemIDplus&query=1415119-52-6&input_type=text.
- ↑ Walker, Tracey (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas.". Managed Healthcare Executive: 47. http://go.galegroup.com/ps/i.do?id=GALE%7CA440401487&v=2.1&it=r&p=GPS&sw=w&asid=711ead20380f089d56147e239e6804ca. Retrieved March 12, 2016.
- ↑ "Hepatitis C virus NS5A inhibitors and drug resistance mutations". World Journal of Gastroenterology 20 (11): 2902–12. March 2014. doi:10.3748/wjg.v20.i11.2902. PMID 24659881.
- ↑ "ACH-3102 resources". Achillion Pharmaceuticals. Winter 2011. http://www.achillion.com/ACH3102_resources.
- ↑ "Achillion gets FDA incentives for hepatitis C drug". 15 May 2012. http://www.businessweek.com/ap/2012-05/D9UP7TCG0.htm.
- ↑ Levin, Jules (18–22 April 2012). "Preclinical characteristics of ACH-3102". 47th Annual Meeting. Barcelona, Spain: European Association for the Study of the Liver. http://www.natap.org/2012/EASL/EASL_79.htm.
- ↑ "Odalasvir - Achillion Pharmaceuticals". AdisInsight. 29 July 2021. https://adisinsight.springer.com/drugs/800031576.
 |  |
